Poster Listings Session 70 <strong>CROI</strong> 2013 305 Avidity of HIV-1-specific CD8 T Cell Responses through Selena Vigano* 1 , F Bellutti-Enders1 , A-L Savoye1 , V Rozot1 , C Cellerai1 , M Cavassini1 , S Ding2 , P-A Bart1 , G Pantaleo1,3 , and A Harari1,3 1 2 Lausanne Univ Hosp, Switzerland;; eurovacc, Amsterdam, The Netherlands;; and 3Swiss Vaccine Res Inst, Lausanne 306 Markers of HIV Disease Progression and Attenuates Anti-HIV T Cell Responses in vitro Basile Siewe* 1 , J Stapleton2 , J Martinson1 , A Kesharvazian1 , I Pandrea3 , A French1,4 , P Demarais4 , and A Landay1 1 2 Rush Univ Med Ctr, Chicago, IL, US;; Univ of Iowa and Iowa City VAMC, US;; 3Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; and 4CORE Ctr, Stroger Hosp of Cook County, Chicago, IL, US 307 Mutations within HLA-B*5701-restricted Epitopes Marcus Buggert* 1 , M Norstrom1 , M Salemi2 , F Hecht3 , and A Karlsson1 1 2 Karolinska Inst, Stockholm, Sweden;; Univ of Florida, Gainesville, US;; and 3 317 in Virologically Suppressed ART-treated Patients Miriam Lichtner*, R Rossi, C Mascia, R Marocco, T Tieghi, F Mengoni, G Russo, P Zuccala, C Mastroianni, and V Vullo Sapienza Polo Pontino Univ of Rome, Italy 318 Early Treatment Leads to a Better Profile of HIV S Hue Univ of California, San Francisco, US 1 , Laurent Hocqueloux* 2 , M Surenaud1 , C Manier1 , J Guignard2 , C Poillet1 , T Prazuck2 , C Lacabaratz1 , and Y Levy1 1 2 INSERM U955, Creteil, France and Ctr Hosp Regional d’Orleans, France 319 The Long-term Persistence of Monoclonal Gammopathy in Patients on ART Is Associated with Epstein-Barr Virus Replication David Ouedraogo* 1,2,3 , A Makinson4 , J-P Vendrell1,2,3 , M-L Casanova4 , A De Jong5 , N Nagot1 , J Reynes4 , P Van de Perre1,3 , and E Tuaillon1,2,3 1 2 INSERM U1058, Univ Montpellier 1, France;; Ctr Hosp Regional Univ de Montpellier, Inst de Recherche en Biotherapies, France;; 3Ctr Hosp Regional Univ de Montpellier, France;; 4Ctr Hosp Regional Univ de Montpellier, UMI 233, France;; and 5Univ de Montpellier, Hosp la Colombiere, France 308 Immune Selection in a Pigtailed Macaque Model of SIV Central Nervous System Disease: Costs and Consequences Sarah Beck*, S Queen, and J Mankowski Johns Hopkins Univ Sch of Med, Baltimore, MD, US c Monday, 2:30-4 pm; Hall B2 Session 71–Poster Abstracts Immune Restoration 311 Successful HIV Suppression Emma Devitt* 1 , JM Rodriguez 1 , S Mandalia 1,2 , and A Pozniak 1 1 Chelsea and Westminster Hosp, London, UK and 2 Imperial Coll London, UK + 312 T Cells Is Associated with Impaired Immunological Recovery in HIV + Patients under HAART A Sennepin1,2,3 , F Baychelier1,3 , R Ho Tsong Fang2 , C Katlama4 , A Simon5 , J Crouzet2 , V Vieillard1,3 , and Patrice Debre* 1,3 1 2 INSERM UMRS 945, Paris, France;; Innavirvax SA, Evry, France;; 3 4 Unive Pierre et Marie Curie, Paris-6, France;; Hosp Pitie-Salpetriere, Svc des Maladies Infectieuses, Paris, France;; and 5Hosp Pitie-Salpetriere, Svc de Med Interne, Paris, France 315 Hyaluronic Acid as a Predictor of Immune Reconstitution following ART Ala Dababneh* 1 , N Cummins 1 , G Bren 1 , Z Temesgen 1 , D Bangsberg 2 , and A Badley 1 1 Mayo Clin, Rochester, MN, US and 2 Massachusetts Gen Hosp, Harvard Med Sch, Boston, US 316 The Effect of HAART-induced HIV Viral Suppression on Markers of Immune Activation in the Multicenter AIDS Cohort Study Nikolas Wada* 1 , L Jacobson 1 , J Margolick 1 , E Breen 2 , and J Bream 1 1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US and 2 Univ of California, Los Angeles, US 30 20th Conference on Retroviruses and Opportunistic Infections c Wednesday, 2:30-4 pm; Hall B2 Session 72–Poster Abstracts Microbial Translocation 320 Diminished in Chronic Untreated HIV Infection Bjorn Corleis*, W Gostic, and D Kwon Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US 309 Phenotypic CD8 + T Cell Defects in Treated HIV Infection Are Sulggi Lee* 1 , E Sinclair1 , Y Huang1 , M Van Natta2 , D Bangsberg3 , M Lederman4 , F Hecht1 , J Martin1 , S Deeks1 , and P Hunt1 1 2 Univ of California, San Francisco, US;; Johns Hopkins Univ, Baltimore, MD, US;; 3Massachusetts Gen Hosp and Harvard Univ, Boston, US;; and 4Case Western Reserve Univ, Cleveland, OH, US 310 Independent of the cART Regimen and Is Not Correlated Norma Rallon* 1 , B Torres2 , A Diaz2 , L Alos2 , E Martinez2 , A Leon2 , J Gatell2 , V Soriano1 , F Garcia2 , and JM Benito1 321 Tight Junction mRNA Expression Decreases with a Proximal Charlotte Chung* and A Levine Case Western Reserve Univ Sch of Med, Cleveland, OH, US 322 AIDS Virus Associated Gut Epithelial Barrier Dysfunction Is Christopher Gaulke* 1 2 Hosp Carlos III, Madrid, Spain and Hosp Clin, Univ of Barcelona, Spain 1 , I Grishina1 , M George1 , J Fass1 , N Joshi1 , J Jovel2 , S-W Ding2 , D Lin1 , and S Dandekar1 1 2 Univ of California, Davis, US and Univ of California, Riverside, US 323 Phenotype Amanda Steele*, E Lee, Z Dong, B Vestal, J Koeppe, and C Wilson Univ of Colorado Anchutz Med Campus, Aurora, US 324 Immune Activation and T Cell Cycling Are Increased in Treated HIV Infection and Inflammatory Bowel Disease;; Nicholas Funderburg*, S Stubblefield-Park, H Sung, G Hardy, B Clagett, J Ignatz-Hoover, C Harding, J Katz, M Lederman, and A Levine Case Western Reserve Univ, Cleveland, OH, US 313 Occurred Early and Was Greater in Those with More Advanced HIV-associated Immunodeficiency Denise Hsu* 1,2 , S Kerr1,2 , T Iampornsin2 , S Pett1 , A Avihingsanon2 , P Thongpaeng2 , S Ubolyam2 , J Ananworanich2 , A Kelleher1 , and D Cooper1 1The Kirby Inst for Infection and Immunity in Society, Univ of New South Wales, Sydney, Australia and 2HIVNAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok 314 HIV + Correlates Ranjini Valiathan* 1 , D Gracia2 , and D Asthana1 325 Gut Lactobacillales during HIV Infection Are Associated with Josue Perez-Santiago* 1 2 Univ of Miami Miller Sch of Med, FL, US and Borinquen Hlth Care Ctr, Miami, FL, US 1 , S Gianella1 , M Massanella1 , M Karris1 , S Var1 , D Patel1 , P Jordan1 , S Little1 , D Richman1,2 , and D Smith1,2 1 2 Univ of California, San Diego, La Jolla, US and VA San Diego Hlthcare System, CA, US 326 and Mucosal Immunity after Oral Serum-derived Bovine David Asmuth* 1,2 , J Stombaugh3 , Z-M Ma4,5 , A Albanese1 , E Hodzic4 , P Troia-Cancio2 , N Flynn2 , T Yotter2 , C Miller4,5 , and R Knight3 1 2 VA Northern California Hosp, Mather, US;; Univ of California, Davis Med Ctr, Sacramento, US;; 3Univ of Colorado, Boulder, US;; 4Univ of California, Davis, US;; and 5Ctr for Comparative Med, Davis, CA, US 327 Untreated HIV-1 Infection and Correlate with T Cell Stephanie Dillon* 1 , E Lee1 , G Austin1 , Z Dong1 , K Rufner1 , S Gianella Weibel2 , D Smith2 , and C Wilson1 1 2 Univ of Colorado Anschutz Med Campus, Aurora, US and Univ of California, San Diego, US 328 Bacteria Is Increased in HIV-1 Infection and Is Associated Jennifer Manuzak*, S Dillon, E Lee, and C Wilson Univ of Colorado Anschutz Med Campus, Aurora, US
<strong>CROI</strong> 2013 Session 75 329 Impact of Acute HIV-1 Infection on Th17/Treg Balance and T Cell Activation in the Sigmoid Colon Alexandra Schuetz* 1,2 , Y Phuang-Ngern 1 , R Rerknimitr 3 , I Sereti 4 , M Robb 2 , V Ngauy 1,2 , R Dewar 5 , J Kim 2,6 , M De Souza 1,2 , J Ananworanich 3,6,7 , and RV254/SEARCH 010 Study Team 1 Armed Forces Res Inst of Med Sci, Bangkok, Thailand;; 2 US Military HIV Res Prgm, Walter Reed Army Inst of Res, Silver Spring, MD;; 3 Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand;; 4 NIH, Bethesda, MD, US;; 5 SAIC-Frederick Inc, MD, US;; 6 SEARCH, Bangkok, Thailand;; and 7 The Thai Red Cross AIDS Res Ctr, Bangkok 330 Paucity of Naïve Th17 Precursors as a Potential Cause for Memory Th17 Deficiency in HIV + Individuals Sandrina Da Fonseca* 1 , A Gosselin 1 , R-M Boulassel 2 , J-P Routy 2,3 , N Bernard 2 , C Tremblay 1 , and P Ancuta 1 1 Ctr de Res du Ctr Hosp de lUniv de Montreal Saint Luc, Canada;; 2 Royal Victoria Hosp, McGill Univ Hlth Ctr, Montreal, Canada;; and 3 McGill Univ, Montreal, Canada 331 Translocation and Immune Activation Connie Kim* 1 , C Kovacs2 , G Kandel1,3,4 , S Huibner1 , D Chege1 , K Shahabi1 , E Benko2 , M Loutfy1,2,5 , M Ostrowski1,3 , and R Kaul1,4 1 2 3 Univ of Toronto, Canada;; Maple Leaf Med Clin, Toronto, Canada;; St Michaels Hosp, Toronto, Canada;; 4Univ Hlth Network, Toronto, Canada;; and 5 341 Prolonged Preservation of HIV-specific Cellular Immunity in Recently HIV + Individuals Receiving Maraviroc Intensified HAART AI Kawana-Tachikawa* 1,2 , J Llibre3 , I Bravo3 , R Escrig3 , B Mothe1,3 , J Miro4 , J Gatell4 , A Iwamoto2 , B Clotet1,3 , and C Brander1 1 2 IrsiCaixa AIDS Res Inst, HIVACAT, Badalona, Spain;; Inst of Med Sci, Univ of Tokyo, Japan;; 3Fundacio Lluita Contra La Sida, Hosp Univ Germans Trias i Pujol, Badalona, Spain;; and 4Hosp Clin, IDIBAPS, Univ of Barcelona, Spain c Monday, 2:30-4 pm; Hall B2 Session 73–Poster Abstracts Immune Activation/Function in HIV Infection 332 Circulating Microparticles as Markers of Immune Activation in Treatment-naïve HIV + Patients B Smit, Willem Blok*, M Van Schilfgaarde, W Terpstra, G Van den Berk, A Leyte, and K Brinkman OLVG Hosp, Amsterdam, The Netherlands 333 The Effect of HIV Infection on Markers of Inflammation among Men with Known HIV Seroconversion Dates in the Multicenter AIDS Cohort Study Heather McKay* 1 , J Bream 1 , J Margolick 1 , O Martinez-Maza 2 , J Phair 3 , C Rinaldo 4 , and L Jacobson 1 1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 2 Univ of California, Los Angeles, US;; 3 Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US;; and 4 Univ of Pittsburgh Sch of Publ Hlth, PA, US 334 Seronegative Intravenous Drug Users that Share Needles Compared to Non-sharing IDU Controls Costin Tomescu* 1 , P Smith2 , D Metzger2 , and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US and Univ of Pennsylvania, Philadelphia, US 335 Translocation in Primary HIV Infection M Chevalier1,2 , G Petitjean1 , C Didier1 , C Dunyach-Remy3,4 , P-M Girard5 , L Meyer6 , J-P Lavigne3,4 , F Barre-Sinoussi1 , D Scott-Algara1 , and Laurence Weiss* 1,7,8 1 2 Inst Pasteur, Paris, France;; Univ Paris Diderot, Sorbonne Paris Cite, France;; 3INSERM U1047, Univ Montpellier 1, UFR de Medecine, Nimes, France;; 4Ctr Hosp Univ Caremeau, Nimes, France;; 5Hosp Saint-Antoine, Paris, France;; 6INSERM U 1018, Univ Paris Sud, France;; 7Univ Paris Descartes, Sorbonne Paris Cite, France;; and 8 c Monday, 2:30-4 pm; Hall B2 Session 75–Poster Abstracts Mucosal Factors in HIV Transmission and Infection 344 Cindy Liu* Hosp Europeen Georges Pompidou, Paris, France 1,2,3 , B Hungate3 , A Tobian2,4 , D Serwadda5 , R Lester1 , G Kigozi5 , R Galiwango5 , M Wawer4 , R Gray4 , and L Price1,6 1 2 Translational Genomics Res Inst, Flagstaff, AZ, US;; Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 3Northern Arizona Univ, Flagstaff, US;; 4Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 5 6 Rakai Hlth Sci Prgm, Entebbe, Uganda;; and George Washington Univ Sch of Publ Hlth, Washington, DC, US 345 and Implications of HIV Transmission Minh Dinh*, R Veazey, and T Hope Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US + 337 Plasma Neeru Bhardwaj* and J Coffin Tufts Univ, Boston, MA, US c Monday, 2:30-4 pm; Hall B2 Session 74–Poster Abstracts Immune Activation, T Cell Homeostasis, and Therapy 338 Augmented Interferon Responses and Inflammation Associated with Altered Tryptophan and Adrenal Steroid Edana Cassol* 1,2 , V Misra 1 , S Morgello 3 , and D Gabuzda 1,2 1 Dana-Farber Cancer Inst, Boston, MA, US;; 2 Harvard Med Sch, Boston, MA, US;; and 3 Mt Sinai Med Ctr, New York, NY, US 339 Infection Jeffrey Ahlers* 1 , R-P Sekaly 1 , M Cameron 1 , K Ghneim 1 , A Filali 1 , M Ghannoum 2 , P Mukherjee 2 , C Shive 3 , B Rodriguez 3 , and M Lederman 3 1 Vaccine and Gene Therapy Inst-Florida, Port St Lucie, US;; 2 Ctr for Med Mycology and OHARA Case Mycology Unit, Cleveland, OH, US;; and 3 Case Western Reserve Univ, Cleveland, OH, US 340 Lower Activation in Periphery and Cervical Tissue Gene Expression Associates with Highly Exposed HIV-1 Shaheed Abdulhaqq* 1,2 , C Tomescu 1 , V Tamayo 3 , L Azzoni 1 , S Garced 3 , L Showe 1 , C Irizarry 3 , C Zorrilla 3 , and L Montaner 1 1 The Wistar Inst, Philadelphia, PA, US;; 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; and 3 Univ of Puerto Rico, Sch of Med, San Juan 342 Clinical Impact of Altered T Cell Homeostasis in Treated HIV + P Ndumbi 1 , J Gillis 2 , J Raboud 2,3 , M Loufty 4 , M Klein 5 , N Machouf 6 , C Cooper 7 , R Hogg 8,9 , A Burchell 10 , Christos Tsoukas* 1 , and Canadian Observational Cohort Collaboration 1 McGill Univ Hlth Ctr, Montreal, Canada;; 2 Univ Hlth Network, Toronto, Canada;; 3 Dalla Lana Sch of Publ Hlth, Univ of Toronto, Canada;; 4 Maple Leaf Med Clin, Toronto, Canada;; 5 Montreal Chest Inst, McGill Univ Hlth Ctr, Canada;; 6 Clin Med l’Actuel, Montreal, Canada;; 7 Ottawa Hosp, Univ of Ottawa, Canada;; 8 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; 9 Faculty of Hlth Sci, Simon Fraser Univ, Burnaby, Canada;; and 10 Ontario HIV Treatment Network, Toronto, Canada + 343 T Cell Response to an Immunodominant Epstein-Barr Virus Epitope A Lucas1 , V Meyer-Pannwitt1 , E McKinnon1 , S Burrows2 , M Rist2 , S Leary1 , M Lucas1 , S Mallal1,3 , and Elizabeth Phillips* 1,3,4 1 2 Inst for Immunology and Infectious Diseases;; Queensland Inst for Med Res;; 3Royal Perth Hosp;; and 4Sir Charles Gairdner Hosp 336 Multiple Imputations and Bayesian Simulations Livio Azzoni* 1 , R Barbour2 , A Violari3 , M Cotton4 , D Glencross3 , W Stevens3 , E Papasavvas1 , A Babiker5 , D Gibb5 , and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US;; Yale Univ, New Haven, CT, US;; 3 4 Univ of the Witwatersrand, Johannesburg, South Africa;; Stellenbosch Univ, Cape Town, South Africa;; and 5 346 Effect of Schistosomiasis Infection on HIV-1 Target Cells in Jessica Prodger* MRC, London, UK 1 , A Ssemaganda2 , N Kiwanuka2,3 , A Ssetaala2 , A Nanvubya2 , L Nielsen4 , P Kato2 , and R Kaul1 1 2 Univ of Toronto, Canada;; Uganda Virus Res Inst-Intl AIDS Vaccine Initiative, Entebbe;; 3Makerere Univ Coll of Hlth Sci, Kampala Uganda;; and 4Intl AIDS Vaccine Initiative, New York, NY, US <strong>Program</strong> 31 Poster Listings 347 Targets of Infection During Sexual Transmission D Stieh 1 , D Maric 1 , K Rothwangl 1 , B Beilfuss 1 , M Anderson 1 , R Veazey 2 , R Ruprecht 3 , F Villinger 4 , and Thomas Hope* 1 1 Northwestern Univ, Chicago, IL, US;; 2 Tulane Univ, New Orleans, LA, US;; 3 Harvard Univ, Boston, MA, US;; and 4 Emory Univ, Atlanta, GA, US 348 in Seminal Plasma and Cervical Mucus Susan Schader* 1 , C Gioia 1 , S Baig 1 , E Allen 1 , E Spongberg 1 , S Allen 1 , G Cianci 1 , D Stieh 1 , P Kiser 2 , and T Hope 1 1 Northwestern Univ, Chicago, IL, US and 2 Univ of Utah, Salt Lake City, US
- Page 1 and 2: Pocket Program CR I 2O13 20th Confe
- Page 3 and 4: vi General Information CROI 2013 AB
- Page 5 and 6: viii General Information CROI 2013
- Page 7 and 8: x Hotel Information CROI 2013 Map K
- Page 9 and 10: CROI 2013 Session 2 j Sunday, 9 am-
- Page 11 and 12: CROI 2013 Session 8 i Monday, 8:30-
- Page 13 and 14: CROI 2013 Session 12 k Monday, 10 a
- Page 15 and 16: CROI 2013 Session 16 b Monday, 1:30
- Page 17 and 18: CROI 2013 Session 20 e Monday, 4-6
- Page 19 and 20: CROI 2013 Session 26 11:00 85 Impac
- Page 21 and 22: CROI 2013 Session 31 1023 Risk Fact
- Page 23 and 24: CROI 2013 Session 34 e Tuesday, 4-6
- Page 25 and 26: CROI 2013 Session 40 i Wednesday, 8
- Page 27 and 28: CROI 2013 Session 45 11:00 153LB Om
- Page 29 and 30: CROI 2013 Session 49 1103 Attrition
- Page 31 and 32: CROI 2013 Session 52 e Wednesday, 4
- Page 33 and 34: CROI 2013 Session 57 188LB Kelly
- Page 35 and 36: CROI 2013 Session 65 c Tuesday, 2:3
- Page 37: CROI 2013 Session 70 c Wednesday, 2
- Page 41 and 42: CROI 2013 Session 82 369 Transcrip
- Page 43 and 44: CROI 2013 Session 89 413 Risk of Cl
- Page 45 and 46: CROI 2013 Session 93 456 A Longitud
- Page 47 and 48: CROI 2013 Session 100 c Tuesday, 2:
- Page 49 and 50: CROI 2013 Session 106 c Monday, 2:3
- Page 51 and 52: CROI 2013 Session 111 c Wednesday,
- Page 53 and 54: CROI 2013 Session 117 616 Immigran
- Page 55 and 56: CROI 2013 Session 122 656 Compariso
- Page 57 and 58: CROI 2013 Session 125 c Tuesday, 2:
- Page 59 and 60: CROI 2013 Session 131 c Monday, 2:3
- Page 61 and 62: CROI 2013 Session 137 c Tuesday, 2:
- Page 63 and 64: CROI 2013 Session 144 809 Prevalenc
- Page 65 and 66: CROI 2013 Session 150 847 Improving
- Page 67 and 68: CROI 2013 Session 161 885 The Impac
- Page 69 and 70: CROI 2013 Session 171 + 924 Women
- Page 71 and 72: CROI 2013 Session 180 c Wednesday,
- Page 73 and 74: CROI 2013 Session 187 994 Protecti
- Page 75 and 76: CROI 2013 Session 192 1032b Changes
- Page 77 and 78: CROI 2013 Session 197 1074 Alexa
- Page 79 and 80: CROI 2013 Session 199 nd 1113 -lin
- Page 81 and 82: POSTER SESSIONS Poster Hall open fr